For research use only. Not for therapeutic Use.
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity[1][2].
Ecnoglutide induces cAMP but not GLP-1 receptor internalization (EC50 = 0.018 nM)[2].
Ecnoglutide (0.015, 0.15 mg/kg, s.c., a single time) reduces blood glucose, promotes insulin induction, and leads to more pronounced body weight reduction compared to Semaglutide (HY-114118) in db/db mice[2].
Ecnoglutide (1 mg/kg, s.c., rats) shows the T1/2 (h), Tmax (h), Cmax (nM), AUClast (h*nM), MRT (h) values of 11.7, 18 .0, 387.3, 16274.8, 25.4 respectively[2].
| Catalog Number | I044182 |
| CAS Number | 2459531-73-6 |
| Molecular Formula | C₁₉₄H₃₀₄N₄₈O₆₁ |
| Purity | ≥95% |
| Reference | [1]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022. [2]. Guo W, et al. Discovery of ecnoglutide – A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023 Sep;75:101762. |
